share_log
Moomoo 24/7 ·  04/24 16:44

Acrivon Therapeutics Reports A 50% Confirmed Overall Response Rate Observed With ACR-368 In Oncosignature-Positive Gynecological Cancers; Initial Clinical Validation Of AP3 Patient Selection Platform, Demonstrated Ability To Prospectively Predict ACR-368 RECIST Responders

Acrivon Therapeutics 报告称,在 Oncosignature 阳性妇科癌中观察到 ACR-368 的总体缓解率为 50%;AP3 患者选择平台的初步临床验证,显示出前瞻性预测 ACR-368 RECIST 反应者的能力

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发